Proactive therapeutic drug monitoring enhances markers of disease activity in patients with Crohn's disease, suggesting benefits for treatment.
Objects The benefit of a proactive therapeutic drug monitoring (TDM) strategy in patients with inflammatory bowel disease receiving biological therapy remains disputed. We aimed to evaluate whether optimizing serum adalimumab levels (s-ADL), guided by proactive TDM, is associated with improved markers of disease activity in patients with Crohn's disease.
No takes yet. Share an insight, caveat, or question.
Carlsen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: